

(20486)

<b>Medical Benefit</b>		<b>Effective Date:</b> 10/01/17	<b>Next Review Date:</b> 05/23
<b>Preauthorization</b>	Yes	<b>Review Dates:</b> 05/13, 05/14, 05/15, 05/16, 05/17, 05/18, 05/19, 05/20, 05/21, 05/22	

**Preauthorization is required.**

*The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.*

**RELATED PROTOCOL**

None

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> <li>Who are male and have signs and symptoms of a dystrophinopathy</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Genetic testing for DMD gene variants to confirm diagnosis without biopsy</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Standard workup without genetic testing, including possible muscle biopsy</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Test accuracy</li> <li>Test validity</li> <li>Symptoms</li> <li>Change in disease status</li> <li>Morbid events</li> <li>Quality of life</li> <li>Medication use</li> <li>Resource utilization</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>Who are female and are a relative of a patient with a DMD-associated dystrophinopathy</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Targeted DMD testing for a known familial variant to determine carrier status</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Standard workup without genetic testing, including family history and cardiac surveillance</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Test accuracy</li> <li>Test validity</li> <li>Changes in reproductive decision making</li> <li>Symptoms</li> <li>Change in disease status</li> <li>Morbid events</li> <li>Quality of life</li> <li>Medication use</li> <li>Resource utilization</li> </ul>

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> <li>Who are asymptomatic male offspring of a female DMD familial variant carrier</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Targeted DMD testing for a known familial variant to determine DMD status</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Standard workup without genetic testing, including family history and cardiac surveillance</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Test accuracy</li> <li>Test validity</li> <li>Symptoms</li> <li>Change in disease status</li> <li>Morbid events</li> <li>Quality of life</li> <li>Medication use</li> <li>Resource utilization</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>Who are an asymptomatic male sibling of a patient with DMD-associated dystrophinopathy</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Targeted DMD testing for a known familial variant to determine DMD status</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Standard workup without genetic testing, including family history and cardiac surveillance</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Test accuracy</li> <li>Test validity</li> <li>Symptoms</li> <li>Change in disease status</li> <li>Morbid events</li> <li>Quality of life</li> <li>Medication use</li> <li>Resource utilization</li> </ul>

## DESCRIPTION

Variants in the Duchenne muscular dystrophy (DMD) gene, which encodes the protein dystrophin, may result in a spectrum of X-linked muscle diseases, including the progressive diseases Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) and dilated cardiomyopathy. Genetic testing can confirm a diagnosis of a dystrophinopathy and distinguish the less from more severe forms, as well as identify female carriers at risk.

## SUMMARY OF EVIDENCE

For individuals who are male and have signs and symptoms of a dystrophinopathy who receive genetic testing for DMD gene variants to confirm diagnosis without biopsy, the evidence includes case series and database entries describing screening and results of types of variants found in patients with clinical signs of DMD or BMD. Relevant outcomes are test accuracy and validity, symptoms, change in disease status, morbid events, quality of life, medication use, and resource utilization. Virtually all males with DMD or BMD have identifiable DMD disease-associated variants, indicating a high clinical sensitivity for genetic testing. The clinical utility of DMD gene testing can be established for the index case to confirm the diagnosis without a muscle biopsy, to initiate effective treatment, and to distinguish between DMD and the less severe BMD. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are female and are a relative of a patient with a DMD-associated dystrophinopathy who receive targeted DMD testing for a known familial variant to determine carrier status, the evidence includes case series and database entries describing screening and results of types of variants found in patients with clinical signs of DMD or BMD. Relevant outcomes are test accuracy and validity, changes in reproductive decision making, symptoms, change in disease status, morbid events, quality of life, medication use, and resource utilization. Published data for the clinical validity for testing for a known familial variant are lacking but validity is expected to be high. Direct evidence on the clinical utility of DMD gene testing in at-risk female relatives is lacking. However, the chain of evidence is strong, because determination of carrier status in a female for a DMD familial variant necessitates or eliminates the need for routine cardiac surveillance and can indicate the likelihood of an affected offspring in women considering children. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are asymptomatic male offspring of a female DMD familial variant carrier or an asymptomatic male sibling of a patient with a DMD-associated dystrophinopathy who receive targeted DMD testing for a known familial variant to determine DMD status, the evidence includes case series and database entries. Relevant outcomes are test accuracy and validity, symptoms, change in disease status, morbid events, quality of life, medication use, and resource utilization. Published data for clinical validity of testing for a known familial variant are lacking, but validity is expected to be high. Direct evidence on the clinical utility of DMD gene testing in asymptomatic male offspring of a female DMD familial variant carrier or male sibling of a patient with a DMD-associated dystrophinopathy is also lacking. However, the chain of evidence is strong, because detection of the DMD familial variant necessitates or eliminates the need for increased medical surveillance or cardiac surveillance in an asymptomatic male offspring of a female carrier or the asymptomatic male sibling of a patient with a DMD-associated dystrophinopathy. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

## POLICY

Genetic testing for *DMD* gene variants for Duchenne or Becker muscular dystrophy may be considered **medically necessary** under the following conditions:

- In a male with signs and symptoms of a dystrophinopathy in order to confirm the diagnosis and direct treatment.
- For at-risk female relatives: (see Policy Guidelines)
  - To confirm or exclude the need for cardiac surveillance
  - For preconception testing to determine the likelihood of an affected offspring in a woman considering a pregnancy.
- For at-risk male offspring (see Policy Guidelines):
  - To confirm or exclude the need for medical and cardiac surveillance.

Genetic testing for *DMD* gene variants is considered **investigational** in all other situations.

## POLICY GUIDELINES

### *DMD* GENE TESTING

Females heterozygous for a Duchenne muscular dystrophy (*DMD*) disease-associated variant are at increased risk for cardiomyopathy and need routine cardiac surveillance and treatment.

At-risk females are defined as first- and second-degree female relatives and include the proband's mother, female siblings of the proband, female offspring of the proband, the proband's maternal grandmother, maternal aunts, and their offspring.

An at-risk male is defined as an asymptomatic male offspring of a female carrier or an asymptomatic male sibling of a patient with a DMD-associated dystrophinopathy.

### GENETIC COUNSELING

Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that

genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

## MEDICARE ADVANTAGE

For Medicare Advantage genetic testing for DMD gene variants is considered **not medically necessary**.

## BACKGROUND

### DYSTROPHINOPATHIES

The dystrophinopathies include a spectrum of muscle diseases. The mild end of the spectrum includes asymptomatic increases in serum concentration of creatine phosphokinase and clinical symptoms such as muscle cramps with myoglobinuria and/or isolated quadriceps myopathy. The severe end of the spectrum includes progressive muscle diseases that lead to substantial morbidity and mortality. When skeletal muscle is primarily affected, the disease is classified as Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD); when the heart is primarily affected, the disease is classified as DMD-associated dilated cardiomyopathy (left ventricular dilation and heart failure).

### Duchenne Muscular Dystrophy

DMD, the most common muscular dystrophy, is a severe childhood X-linked recessive disorder that results in significant disability due to skeletal myopathy and cardiomyopathy. The disease is characterized by progressive, symmetric muscle weakness and gait disturbance resulting from a defective dystrophin gene.<sup>1</sup> According to a 2014 systematic review, the incidence of DMD ranges from 1 in 3600 to 1 in 9300 male births.<sup>2</sup> Approximately one-third of DMD cases arise from de novo variants and have no known family history.<sup>1</sup> Infant males with DMD are often asymptomatic. Manifestations may be present as early as the first year of life in some patients, but clinical manifestations most often appear during preschool, from years 2 to 5. Affected children present with gait problems, calf hypertrophy, positive Gower sign, and difficulty climbing stairs. The affected child's motor status may plateau between 3 and 6 years of life with deterioration beginning at 6 to 8 years. Most patients will be wheelchair-bound by ages 9 to 12 years but will retain preserved upper-limb function until a later period. Cardiomyopathy occurs after 18 years of age. Late complications are cardiorespiratory (e.g., decreased pulmonary function as a result of respiratory muscle weakness and cardiomyopathy). These severe complications commonly appear in the second decade of life and eventually lead to death.<sup>1</sup> Few individuals with DMD survive beyond the third decade.

### Becker Muscular Dystrophy

BMD is characterized by later onset skeletal muscle weakness. Individuals remain ambulatory into their 20s. Despite the milder skeletal muscle involvement, heart failure from cardiomyopathy is a common cause of morbidity and the most common cause of death in these patients, with a mean age of death in the mid-40s.<sup>3</sup>

### FEMALE CARRIERS

Females heterozygous for a *DMD* disease-associated variant can manifest symptoms of the disease.<sup>4</sup> An estimated 2.5% to 7.8% of female carriers are manifesting carriers who develop symptoms ranging from mild muscle weakness to a rapidly progressive DMD-like muscular dystrophy.<sup>5</sup> Female carriers are at increased risk for dilated cardiomyopathy. Most heterozygous women do not show severe myopathic features of DMD, possibly due to compensation by a normal X chromosome with inactivation of the mutated *DMD* gene in the affected X chromosome.<sup>6</sup> In some cases, this compensation can be reversed by a nonrandom or skewed inactivation of the X chromosome, resulting in greater expression of the affected X chromosome and some degree of myopathic

features.<sup>7</sup> Other mechanisms of manifesting female carriers include X chromosome rearrangement involving the *DMD* gene and complete or partial absence of the X chromosome (Turner syndrome).<sup>4</sup>

#### CLINICAL DIAGNOSIS

##### Duchenne Muscular Dystrophy

Suspicion of DMD should be considered irrespective of family history; it is most commonly triggered by the observation of abnormal muscle function in a male child, the detection of an increase in serum creatine kinase tested for unrelated indications, or detection of increased serum transaminases (aspartate aminotransferase and alanine aminotransferases). Clinical examination by a neuromuscular specialist for DMD includes visual inspection of mechanical function such as running, jumping, climbing stairs, and getting up from the floor. Common presenting symptoms include abnormal gait with frequent falls, difficulties rising from the floor or tip-toe walking, and pseudohypertrophy of the calves. A clinical examination may reveal decreased or lost muscle reflexes and, commonly, a positive Gower sign. An elevation of serum creatine kinase, at least 10 to 20 times normal levels (between 5000 IU/L and 150000 IU/L), is nonspecific to DMD but is always present in affected patients.<sup>1</sup> Electromyography and nerve conduction studies were traditional parts of the assessment of neuromuscular disorders, but these tests may not be necessary for assessment of DMD.<sup>8</sup> An open skeletal muscle biopsy is needed when a test for deletions or duplications of the *DMD* gene is negative. The biopsy will provide general signs of muscular dystrophy, including muscle fiber degeneration, muscle regeneration, and increased content of connective tissue and fat. Dystrophin analysis of a muscle biopsy will always be abnormal in affected patients but is not specific to DMD.

##### Becker Muscular Dystrophy

BMD is clinically similar to DMD but is milder and has a later onset. BMD presents with progressive symmetric muscle weakness, often with calf hypertrophy, although the weakness of quadriceps femoris may be the only sign. Activity-induced cramping may be present in some individuals, and flexion contractures of the elbows may be present late in the course. Neck flexor muscle strength is preserved, which differentiates BMD from DMD. Serum creatine kinase shows moderate-to-severe elevation (5 to 100 times the normal level).

##### Molecular Diagnosis

*DMD* is the only gene of which variants are known to cause DMD, BMD, and *DMD*-associated cardiomyopathy. Molecular genetic testing of *DMD* can establish the diagnosis of a dystrophinopathy without muscle biopsy in most patients with DMD and BMD.

The dystrophinopathies are X-linked recessive and penetrance is complete in males. The gene that codes for dystrophin is the largest known human gene.<sup>1</sup> A molecular confirmation of DMD and BMD is achieved by confirming the presence of a pathogenic variant in this gene by a number of available assays. The large size of the dystrophin gene results in a complex variant spectrum with over 5000 reported disease-associated variants, as well as a high spontaneous de novo variant rate.<sup>9</sup>

##### Treatment

There is no cure for DMD or BMD. Treatment is aimed at controlling symptoms to improve quality of life. However, the natural history of the disease can be changed by strategies such as corticosteroid therapy, proper nutrition, or rehabilitative interventions. Glucocorticoids were shown in a 1991 randomized controlled trial (RCT) to prolong the period of independent ambulation by 3 years.<sup>10</sup> The goal of this therapy is to preserve ambulation and minimize later respiratory, cardiac, and orthopedic complications. Glucocorticoids work by decreasing inflammation, preventing fibrosis, improving muscle regeneration, improving mitochondrial function, decreasing oxidative radicals, and stopping abnormal apoptosis pathways.<sup>1</sup> Bone density measurement and immunization are prerequisites for corticosteroid therapy initiation, which typically begins at 2 to 5 years of age, although there has been no demonstrated benefit of therapy before 5 years of age.<sup>1</sup>

New therapeutic trials require accurate diagnoses of these disorders, especially when the therapy is targeted at specific pathogenic variants.<sup>11</sup> Exon-skipping is a molecular therapy aimed at skipping the transcription of a targeted exon to restore a correct reading frame using antisense oligonucleotides. Exon-skipping may result in a DMD protein without the mutated exon and a normal, nonshifted reading frame. Exon-skipping may also restore DMD protein function so that the treated patient's phenotypic expression more closely resembles BMD. Several therapies are currently in clinical trials. Exon-skipping therapies using antisense oligonucleotides approved by the U.S. Food and Drug Administration include: eteplirsen (Exondys 51) for treatment for patients who have a confirmed variant of the dystrophin gene amenable to exon 51 skipping,<sup>12</sup> golodirsen (Vyondys 53),<sup>13</sup> and viltolarsen (Viltepso)<sup>14</sup> for patients who have a confirmed mutation of the *DMD* gene that is amenable to exon 53 skipping. These approvals were based on improvements in the surrogate outcome of increased dystrophin production in skeletal muscle and benefits in clinical outcomes have not yet been established.

### REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

---

Services that are the subject of a clinical trial do not meet our Technology Assessment and Medically Necessary Services Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment and Medically Necessary Services Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

### REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Verma S, Anziska Y, Cracco J. Review of Duchenne muscular dystrophy (DMD) for the pediatricians in the community. *Clin Pediatr (Phila)*. Nov 2010;49(11):1011-7. PMID 20724320
2. Mah JK, Korngut L, Dykeman J, et al. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. *Neuromuscul Disord*. Jun 2014;24(6):482-91. PMID 24780148
3. Darras BT, Miller DT, Urion DK. Dystrophinopathies. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. *GeneReviews*. Seattle, WA: University of Washington; 2014.
4. Yoon J, Kim SH, Ki CS, et al. Carrier woman of Duchenne muscular dystrophy mimicking inflammatory myositis. *J Korean Med Sci*. Apr 2011;26(4):587-91. PMID 21468271
5. Soltanzadeh P, Friez MJ, Dunn D, et al. Clinical and genetic characterization of manifesting carriers of DMD mutations. *Neuromuscul Disord*. Aug 2010;20(8):499-504. PMID 20630757
6. Bonilla E, Schmidt B, Samitt CE, et al. Normal and dystrophin-deficient muscle fibers in carriers of the gene for Duchenne muscular dystrophy. *Am J Pathol*. Dec 1988;133(3):440-5. PMID 3059802

7. Yoshioka M, Yorifuji T, Mituyoshi I. Skewed X inactivation in manifesting carriers of Duchenne muscular dystrophy. *Clin Genet*. Feb 1998;53(2):102-7. PMID 9611069
8. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *Lancet Neurol*. Jan 2010;9(1):77-93. PMID 19945913
9. Mah JK, Selby K, Campbell C, et al. A population-based study of dystrophin mutations in Canada. *Can J Neurol Sci*. May 2011;38(3):465-74. PMID 21515508
10. Griggs RC, Moxley RT, Mendell JR, et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. *Arch Neurol*. Apr 1991;48(4):383-8. PMID 2012511
11. Abbs S, Tuffery-Giraud S, Bakker E, et al. Best practice guidelines on molecular diagnostics in Duchenne/Becker muscular dystrophies. *Neuromuscul Disord*. Jun 2010;20(6):422-7. PMID 20466545
12. Food and Drug Administration (FDA). FDA News Release: FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. 2016; <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm521263.htm>. Accessed January 17, 2022.
13. Food and Drug Administration. VYONDYS 53 (golodirsen) Prescribing Information. 2019 [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2019/211970s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211970s000lbl.pdf) Accessed January 19, 2022.
14. Food and Drug Administration. VILTEPSO (viltolarsen) Prescribing Information. 2020. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/212154Orig1s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212154Orig1s000lbl.pdf). Accessed January 18, 2022.
15. Monaco AP, Bertelson CJ, Liechti-Gallati S, et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. *Genomics*. Jan 1988;2(1):90-5. PMID 3384440
16. Aartsma-Rus A, Van Deutekom JC, Fokkema IF, et al. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. *Muscle Nerve*. Aug 2006;34(2):135-44. PMID 16770791
17. Ross LF, Ross LF, Saal HM, et al. Technical report: Ethical and policy issues in genetic testing and screening of children. *Genet Med*. Mar 2013;15(3):234-45. PMID 23429433
18. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. *Lancet Neurol*. Mar 2018;17(3):251-267. PMID 29395989
19. National Government Services, Inc. (Primary Geographic Jurisdiction 06 & K - Illinois, Minnesota, Wisconsin, Connecticut, New York - Entire State, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont) Local Coverage Determination (LCD): Molecular Pathology Procedures (L35000), Revision Effective Date 07/01/2020.